* Enfusion Inc ENFN.N ENFN.K is expected to show a rise
in
quarterly revenue when it reports results on November 7.
* The Chicago Illinois-based company is expected to report
a
12.5% increase in revenue to $44.051 million from $39.15 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
* Refinitiv's mean analyst estimate for Enfusion Inc is for
earnings of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Enfusion
Inc is
$10.5, above its last closing price of $8.33.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.04 0.04 0.04 Met -4.1
Mar. 31 2023 0.03 0.03 0.02 Missed -27.1
Dec. 31 2022 0.03 0.03 0.04 Beat 36.4
Sep. 30 2022 0.01 0.02 0.03 Beat 50
Jun. 0.02 0.02 0.04 Beat 100
30 2022
Mar. 31 2022 0.03 0.03 0.00 Missed -93.6
Dec. 31 2021 0.03 0.04 0.02 Missed -43.6
Sep. 30 2021 0.04 0.04 0.03 Missed -18.9
This summary was machine generated November 3 at 17:47 GMT. All
figures in US dollars unless otherwise stated